In the specification.

The specification is amended to correctly recite the priority of this application. No new matter is added by this Amendment.

If a telephone conference would expedite prosecution of this application, the Examiner is invited to telephone the undersigned at (415) 217-6022.

EXPRESS MAIL LABEL NO:
EL707914877US

Respectfully submitted,

Peter K. Seperack

Peter K. Seperack
Attorney for Applicant(s)
Reg. No. P-47,932

APPENDIX I

CLAIMS PENDING AS OF DECEMBER 4, 2000

1. A method for screening a test compound for the ability to activate transcription through an indirect estrogen response, the method comprising:

a) providing a cell comprising an estrogen receptor and a promoter comprising an AP1 site which regulates expression of a reporter gene;

b) contacting the cell with the test compound; and

c) detecting the expression of the reporter gene.

2. (Amended) A method of claim 1, wherein the cell is an Ishikawa cell.

3. (Amended) A method of claim 1, wherein the cell over-expresses the estrogen receptor.

4. (Amended) The method of claim 1, wherein the promoter is genetically engineered to comprise an AP1 site.

5. (Amended) The method of claim 1, wherein the test compound is known to have antiestrogenic activity.

6. (Amended) The method of claim 1, wherein the cell is derived from uterine tissue.

7. (Amended) The method of claim 6, wherein the cell is a HeLa cell or an Ishikawa cell.

8. (Amended) A method of claim 1, further comprising the steps of:

a) providing a second cell comprising an estrogen receptor and a promoter comprising a standard estrogen response element which regulates expression of a second reporter gene;

b) contacting the second cell with the test compound, and

c) detecting the expression of the second reporter gene.

9. (Amended) A method of claim 8, wherein the response element is from the *Xenopus* vitellogenin A2 gene.

10. (Amended) A method of claim 1, wherein the cell further comprises a promoter comprising a standard estrogen response element which regulates expression of second reporter gene.

11. (Amended) A method of claim 10, wherein the response element is from the *Xenopus* vitellogenin A2 gene.

12. (Amended) An estrogen agonist identified by the method of claim 1.

13. A method for screening a test compound for the ability to inhibit transcription through an indirect estrogen response, the method comprising:

a) providing a cell comprising an estrogen receptor and a promoter comprising an AP1 site which regulates expression of a reporter gene;

b) contacting the cell with the test compound an a compound known to mediate an indirect estrogen response;

c) detecting the expression of the reporter gene.

14. (Amended) The method of claim 13, wherein the compound is known to mediate an indirect estrogen response is tamoxifen.

15. (Amended) A method of claim 13, wherein the cell over-expresses the estrogen receptor.

16. (Amended) The method of claim 13, wherein the promoter is genetically engineered to comprise an AP1 site

(Amended) A compound identified by the method of claim 13.

18. A method for screening a test environmental compound for estrogenic activity, the method comprising:

a) providing a cell comprising an estrogen receptor and a promoter comprising an estrogen response element which regulates the expression of a reporter gene;

b) contacting the cell with the test compound; and

c) detecting the expression of the reporter gene.

19. (Amended) The method of claim 18, wherein the cell further comprises a promoter comprising an AP1 site which regulates expression of a second reporter gene.

20. (Amended) The method of claim 18, wherein the reporter gene is CAT.

21. (Amended) The method of claim 18, wherein the cell over-expresses the estrogen receptor.

22. (Amended) The method of claim 18, wherein the cell is an ERC1 cell.

23. A method of inhibiting agonistic activity of an antiestrogen compound, said method comprising administering with said antiestrogen compound an inhibitor selected from the group consisting of genistein, staurosporine, 6-thioguanine, and 2 aminopurine.

24. (Amended) The method of claim 23, wherein said inhibiting agonistic activity comprises inhibiting an indirect estrogen response.

25. (Amended) The method of claim 23, wherein said antiestrogen compound is tamoxifen.

26. (Amended) The method of claim 23, wherein said inhibition is *in vivo*.